» Articles » PMID: 33761428

Maternal Continuous Oral Oxycodone Self-administration Alters Pup Affective/social Communication but Not Spatial Learning or Sensory-motor Function

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2021 Mar 24
PMID 33761428
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The broad use/misuse of prescription opioids during pregnancy has resulted in a surge of infants with Neonatal Opioid Withdrawal Syndrome (NOWS). Short-term irritability and neurological complications are its hallmarks, but the long-term consequences are unknown.

Methods: A newly-developed preclinical model of oxycodone self-administration enables adult female rats to drink oxycodone (∼10/mg/kg/day) before and during pregnancy, and after delivery, and to maintain normal liquid intake, titrate dosing, and avoid withdrawal.

Results: Oxycodone was detected in the serum of mothers and pups. Growth parameters in dams and pups and litter mass and size were similar to controls. There were no differences in paw retraction latency to a thermal stimulus between Oxycodone and Control pups at postnatal (PN) 2 or PN14. Oxycodone and Control pups had similar motor coordination, cliff avoidance, righting time, pivoting, and olfactory spatial learning from PN3 through PN13. Separation-induced ultrasonic vocalizations at PN8 revealed higher call frequency in Oxycodone pups relative to Control pups (p<0.031; Cohen's d=1.026). Finally, Oxycodone pups displayed withdrawal behaviors (p's<0.029; Cohen's d's>0.806), and Oxycodone males only vocalized more than Control pups in the first minute of testing (p's<0.050; Cohen's d's>.866). Significant effects were corroborated by estimation plots.

Conclusions: Our rat model of oral oxycodone self-administration in pregnancy shows exacerbated affect/social communication in pups in a sex-dependent manner but spared cognition and sensory-motor behaviors. This preclinical model reproduces selective aspects of human opioid use during pregnancy, enabling longitudinal analysis of how maternal oxycodone changes emotional behavior in the offspring.

Citing Articles

Adolescent oral oxycodone self-administration disrupts neurobehavioral and neurocognitive development.

McLaurin K, Ott R, Mactutus C, Booze R Neuropharmacology. 2024; 258:110064.

PMID: 38981578 PMC: 11418068. DOI: 10.1016/j.neuropharm.2024.110064.


Neurobehavioral Characterization of Perinatal Oxycodone-Exposed Offspring in Early Adolescence.

Flores A, Nguyen N, Devanaboyina M, Sanketh S, Athota P, Jagadesan S J Neuroimmune Pharmacol. 2024; 19(1):29.

PMID: 38874861 DOI: 10.1007/s11481-024-10129-7.


Advances in animal models of prenatal opioid exposure.

Ferrante J, Blendy J Trends Neurosci. 2024; 47(5):367-382.

PMID: 38614891 PMC: 11096018. DOI: 10.1016/j.tins.2024.03.005.


Developmental outcomes with perinatal exposure (DOPE) to prescription opioids.

Flores A, Nguyen N, Pendyala G NeuroImmune Pharm Ther. 2023; 2(4):339-351.

PMID: 38058996 PMC: 10696573. DOI: 10.1515/nipt-2023-0017.


Ontogenetic Oxycodone Exposure Affects Early Life Communicative Behaviors, Sensorimotor Reflexes, and Weight Trajectory in Mice.

Minakova E, Sarafinovska S, Mikati M, Barclay K, McCullough K, Dougherty J Front Behav Neurosci. 2021; 15:615798.

PMID: 33692675 PMC: 7937712. DOI: 10.3389/fnbeh.2021.615798.

References
1.
Workman A, Charvet C, Clancy B, Darlington R, Finlay B . Modeling transformations of neurodevelopmental sequences across mammalian species. J Neurosci. 2013; 33(17):7368-83. PMC: 3928428. DOI: 10.1523/JNEUROSCI.5746-12.2013. View

2.
HUTCHINGS D, Zmitrovich A, Brake S, Malowany D, Church S, Nero T . Prenatal administration of methadone using the osmotic minipump: effects on maternal and offspring toxicity, growth, and behavior in the rat. Neurotoxicol Teratol. 1992; 14(1):65-71. DOI: 10.1016/0892-0362(92)90030-e. View

3.
Choi B, Lee Y, An S, Lee S, Lee E, Noh G . Population pharmacokinetics and analgesic potency of oxycodone. Br J Clin Pharmacol. 2016; 83(2):314-325. PMC: 5237696. DOI: 10.1111/bcp.13101. View

4.
Wallin C, Bowen S, Roberge C, Richardson L, Brummelte S . Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model. Drug Alcohol Depend. 2019; 205:107625. DOI: 10.1016/j.drugalcdep.2019.107625. View

5.
Tempel A, Yang J, Basheer R . Prenatal morphine exposure differentially alters expression of opioid peptides in striatum of newborns. Brain Res Mol Brain Res. 1995; 33(2):227-32. DOI: 10.1016/0169-328x(95)00127-e. View